50BA logo

Bicycle Therapeutics DB:50BA Stock Report

Last Price

€11.90

Market Cap

€891.9m

7D

1.7%

1Y

-20.7%

Updated

03 Feb, 2025

Data

Company Financials +

Bicycle Therapeutics plc

DB:50BA Stock Report

Market Cap: €891.9m

50BA Stock Overview

A clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. More details

50BA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Bicycle Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bicycle Therapeutics
Historical stock prices
Current Share PriceUS$11.90
52 Week HighUS$26.00
52 Week LowUS$11.60
Beta0.92
1 Month Change-11.85%
3 Month Change-46.40%
1 Year Change-20.67%
3 Year Change-70.69%
5 Year Changen/a
Change since IPO-49.15%

Recent News & Updates

Recent updates

Shareholder Returns

50BADE BiotechsDE Market
7D1.7%1.0%1.9%
1Y-20.7%-4.3%15.1%

Return vs Industry: 50BA underperformed the German Biotechs industry which returned -4.3% over the past year.

Return vs Market: 50BA underperformed the German Market which returned 15.1% over the past year.

Price Volatility

Is 50BA's price volatile compared to industry and market?
50BA volatility
50BA Average Weekly Movement12.3%
Biotechs Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 50BA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 50BA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2009284Kevin Leewww.bicycletherapeutics.com

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.

Bicycle Therapeutics plc Fundamentals Summary

How do Bicycle Therapeutics's earnings and revenue compare to its market cap?
50BA fundamental statistics
Market cap€891.89m
Earnings (TTM)-€160.41m
Revenue (TTM)€35.60m

25.1x

P/S Ratio

-5.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
50BA income statement (TTM)
RevenueUS$36.90m
Cost of RevenueUS$168.05m
Gross Profit-US$131.15m
Other ExpensesUS$35.12m
Earnings-US$166.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.41
Gross Margin-355.45%
Net Profit Margin-450.64%
Debt/Equity Ratio0%

How did 50BA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 03:27
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bicycle Therapeutics plc is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kalpit PatelB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity